Fang Zhong, Luo Wen-Xin, Wang Ming-Qiao, Chen Ying-Wei, Zhang Jun, Chen Hong-Lin, Guan Yi, Xia Ning-Shao
National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Key Laboratory of Education Minister for Cell Biology and Tumor Cell Engineering of Xiamen University, School of Life Sciences, Xiamen University, Xiamen 361005, China.
Sheng Wu Gong Cheng Xue Bao. 2007 Mar;23(2):292-6. doi: 10.1016/s1872-2075(07)60026-0.
Previously, an mAb 10F7 was developed against H5N1 hemagglutinin, which was highly specific to 34 different H5N1 strains and showed good neutralizing activity. In the present study, the single-chain fragment of the antibody was cloned into a prokaryotic vector and then expressed in E. coli. The activity of the scFv was tested in hemagglution inhibition and neutralization experiment. Two H5N1 virus strains were inhibited to bind erythrocyte cells by the scFv while the H9 virus was not. Also, five H5N1 virus strains were neutralized during infecting MDCK cells. These results showed an approachable method for developing therapeutic antibody to H5N1 virus.
